Start date: 01/10/2012
Duration: 4 years
Total cost: €26.4 million
Project coordinator: GlaxoSmithKline (Philip Dell’Orco)
Managing entity: University of Manchester (Nicholas Turner)
The research leading to these results has received support from the Innovative Medicines Initiative Joint Undertaking under grant agreement n° 115360, resources of which are composed of financial contribution from the European Union’s Seventh Framework Programme (FP7/2007-2013) and EFPIA companies’ in kind contribution.